“…The absence of a provincial drug database for individuals who are covered by private drug insurance in Québec has limited research to patients covered by the public drug insurance. Knowing that the mothers' SES is associated with congenital malformations (Wasserman et al, ; Vrijheid et al, ; Yang et al, ; Kuciene and Dulskiene, ; Olesen et al, ; Varela et al, ; Hunter et al, ) and asthma (Litonjua et al, ; Basagana et al, ; Chung et al, ; Eagan et al, ; Hedlund et al, ; Ellison‐Loschmann et al, ; Ekerljung et al, ), it has been suggested that drug insurance status, which could be considered to be a proxy for SES (Chung et al, ), may be an effect modifier in the association between asthma and congenital malformations. Therefore, to investigate this issue, we conducted a study based on a new, large representative cohort of pregnant women who were selected independently of their drug insurance status.…”